| Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary J Vestbo, SS Hurd, AG Agustí, PW Jones, C Vogelmeier, A Anzueto, ... American journal of respiratory and critical care medicine 187 (4), 347-365, 2013 | 6946 | 2013 |
| Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary CF Vogelmeier, GJ Criner, FJ Martinez, A Anzueto, PJ Barnes, ... American journal of respiratory and critical care medicine 195 (5), 557-582, 2017 | 5159 | 2017 |
| Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019 D Singh, A Agusti, A Anzueto, PJ Barnes, J Bourbeau, BR Celli, GJ Criner, ... European Respiratory Journal 53 (5), 2019 | 2015 | 2019 |
| An angiogenic role for the human peptide antibiotic LL-37/hCAP-18 R Koczulla, G Von Degenfeld, C Kupatt, F Krötz, S Zahler, T Gloe, ... The Journal of clinical investigation 111 (11), 1665-1672, 2003 | 1141 | 2003 |
| Indacaterol–glycopyrronium versus salmeterol–fluticasone for COPD JA Wedzicha, D Banerji, KR Chapman, J Vestbo, N Roche, RT Ayers, ... New England Journal of Medicine 374 (23), 2222-2234, 2016 | 1074 | 2016 |
| Treatable traits: toward precision medicine of chronic airway diseases A Agusti, E Bel, M Thomas, C Vogelmeier, G Brusselle, S Holgate, ... European Respiratory Journal 47 (2), 410-419, 2016 | 1014 | 2016 |
| Tiotropium versus salmeterol for the prevention of exacerbations of COPD C Vogelmeier, B Hederer, T Glaab, H Schmidt, MPMH Rutten-van Mölken, ... New England Journal of Medicine 364 (12), 1093-1103, 2011 | 977 | 2011 |
| Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary A Agustí, BR Celli, GJ Criner, D Halpin, A Anzueto, P Barnes, J Bourbeau, ... European Respiratory Journal 61 (4), 2023 | 924 | 2023 |
| Global initiative for the diagnosis, management, and prevention of chronic obstructive lung disease. The 2020 GOLD science committee report on COVID-19 and chronic obstructive … DMG Halpin, GJ Criner, A Papi, D Singh, A Anzueto, FJ Martinez, ... American journal of respiratory and critical care medicine 203 (1), 24-36, 2021 | 698 | 2021 |
| Symptom variability in patients with severe COPD: a pan-European cross-sectional study R Kessler, MR Partridge, M Miravitlles, M Cazzola, C Vogelmeier, ... European Respiratory Journal 37 (2), 264-272, 2011 | 610 | 2011 |
| An official American Thoracic Society/European Respiratory Society statement: research questions in chronic obstructive pulmonary disease BR Celli, M Decramer, JA Wedzicha, KC Wilson, A Agustí, GJ Criner, ... American journal of respiratory and critical care medicine 191 (7), e4-e27, 2015 | 601 | 2015 |
| Identification of a novel, multifunctional β-defensin (human β-defensin 3) with specific antimicrobial activity: its interaction with plasma membranes of Xenopus oocytes and … JR García, F Jaumann, S Schulz, A Krause, J Rodríguez-Jiménez, ... Cell and tissue research 306, 257-264, 2001 | 594 | 2001 |
| Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial H Watz, K Tetzlaff, EFM Wouters, A Kirsten, H Magnussen, ... The lancet Respiratory medicine 4 (5), 390-398, 2016 | 523 | 2016 |
| Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease P Kardos, M Wencker, T Glaab, C Vogelmeier American journal of respiratory and critical care medicine 175 (2), 144-149, 2007 | 470 | 2007 |
| Antioxidative and Clinical Effects of High-doseN-Acetylcysteine in Fibrosing Alveolitis: Adjunctive Therapy to Maintenance Immunosuppression J Behr, K Maier, B Degenkolb, F Krombach, C Vogelmeier American journal of respiratory and critical care medicine 156 (6), 1897-1901, 1997 | 450 | 1997 |
| Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised … CF Vogelmeier, ED Bateman, J Pallante, VKT Alagappan, P D'Andrea, ... The Lancet Respiratory Medicine 1 (1), 51-60, 2013 | 432 | 2013 |
| Patient understanding, detection, and experience of COPD exacerbations: an observational, interview-based study R Kessler, E Ståhl, C Vogelmeier, J Haughney, E Trudeau, CG Löfdahl, ... Chest 130 (1), 133-142, 2006 | 409 | 2006 |
| The discovery of α1-antitrypsin and its role in health and disease SM Janciauskiene, R Bals, R Koczulla, C Vogelmeier, T Köhnlein, T Welte Respiratory medicine 105 (8), 1129-1139, 2011 | 399 | 2011 |
| Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? C Vogelmeier, A D'Urzo, R Pauwels, JM Merino, M Jaspal, S Boutet, ... European Respiratory Journal 26 (5), 819-828, 2005 | 387 | 2005 |
| European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α1-antitrypsin deficiency M Miravitlles, A Dirksen, I Ferrarotti, V Koblizek, P Lange, R Mahadeva, ... European Respiratory Journal 50 (5), 2017 | 349 | 2017 |
